



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Ikue MORI et al. **Confirmation No.: 4053**
Appl. No.: 10/596,985 **Group Art Unit: 1618**
(National Stage of PCT/JP2005/000009)
I.A. Filed: January 5, 2005 **Examiner: not yet assigned**
For: **METHOD OF SCREENING MOLECULE ASSOCIATED WITH PSYCHIATRIC DISORDER**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Pursuant to 37 C.F.R. § 1.56 and 37 C.F.R. §§ 1.97-1.98 and supplemental to the Information Disclosure Statement filed December 18, 2007, Applicants hereby direct the Examiner's attention to the following documents cited and discussed in the specification of the above-referenced application:

- (1) FIRE et al. "Potent and Specific Genetic Interference by Double-Stranded RNA in *Caenorhabditis elegans*", *Nature*, vol. 391, 1998, pp. 806-811;
Applicants note that this document is cited and discussed in the present application, beginning at page 3, line 19;
- (2) LIEBERMAN et al. "Neurochemical Sensitization in the Pathophysiology of Schizophrenia: Deficits and Dysfunction in Neuronal Regulation and Plasticity", *Neuropsychopharmacology*, vol. 17, no. 4, 1997, pp. 205-229;

Applicants note that this document is cited and discussed in the present application, beginning at page 1, line 19;

(3) LARUELLE "The Role of Endogenous Sensitization in the Pathophysiology of Schizophrenia: Implications from Recent Brain Imaging Studies", *Brain Research Reviews*, vol. 31, 2000, pp. 371-384; Applicants note that this document is cited and discussed in the present application, beginning at page 1, line 19;

(4) ANDRETIC et al. "Requirement of Circadian Genes for Cocaine Sensitization in *Drosophila*", *Science*, vol. 285, 1999, pp. 1066-1068; Applicants note that this document is cited and discussed in the present application, beginning at page 2, line 17;

(5) WOLF "Cocaine Addiction: Clues from *Drosophila* on Drugs", *Current Biology*, vol. 9, 1999, R770-R772; Applicants note that this document is cited and discussed in the present application, beginning at page 2, line 18;

(6) SUO et al. "Identification of a Dopamine Receptor from *Caenorhabditis elegans*", *Neuroscience Letters*, vol. 319, 2002, pp. 13-16; Applicants note that this document is cited and discussed in the present application, beginning at page 2, line 30;

(7) SUO et al. "Cloning and Characterization of a *Caenorhabditis elegans* D2-like Dopamine Receptor", *Journal of Neurochemistry*, vol. 86, 2003, pp. 869-878; Applicants note that this document is cited and discussed in the present application, beginning at page 2, line 31;

(8) NASS et al. "Neurotoxin-Induced Degeneration of Dopamine Neurons in *Caenorhabditis elegans*", Proceedings of the National Academy of Sciences, vol. 99, no. 5, 2002, pp. 3264-3269; Applicants note that this document is cited and discussed in the present application, beginning at page 2, line 31;

(9) ROBINSON et al. "Persistent Structural Modifications in Nucleus Accumbens and Prefrontal Cortex Neurons Produced by Previous Experience with Amphetamine" The Journal of Neuroscience, vol. 17, no. 21, 1997, pp. 8491-8497; Applicants note that this document is cited and discussed in the present application, beginning at page 3, line 10;

(10) THOMAS et al. "Long-Term Depression in the Nucleus Accumbens: A Neural Correlate of Behavioral Sensitization to Cocaine" Nature Neuroscience, vol. 4, no. 12, 2001, pp. 1217-1223; Applicants note that this document is cited and discussed in the present application, beginning at page 3, line 11;

(11) LICATA et al. "The Roles of Calcium/Calmodulin-Dependent and Ras/Mitogen-Activated Protein Kinases in the Development of Psychostimulant-Induced Behavioral Sensitization" Journal of Neurochemistry, vol. 85, 2003, pp. 14-22; Applicants note that this document is cited and discussed in the present application, beginning at page 3, line 11;

(12) ZUBIN et al. "Vulnerability-A New View of Schizophrenia", Journal of Abnormal Psychology, vol. 86, no. 2, 1977, pp. 103-126; Applicants note that this document is cited and discussed in the present application, beginning at page 1, line 13;

(13) AMBELAS "Psychologically Stressful Events in the Precipitation of Manic Episodes", British Journal of Psychiatry, vol. 135, 1979, pp. 15-21; Applicants note that this document is cited and discussed in the present application, beginning at page 1, line 13;

(14) SATO et al." Acute Exacerbation of Paranoid Psychotic State after Long-Term Abstinence in Patients with Previous Methamphetamine Psychosis", Biological Psychiatry, vol. 18, no. 4, 1983, pp. 429-440; Applicants note that this document is cited and discussed in the present application, beginning at page 1, line 18;

(15) PIAZZA et al. "Stress- and Pharmacologically-Induced Behavioral Sensitization Increases Vulnerability to Acquisition of Amphetamine Self-Administration" Brain Research, vol. 514, 1990, pp. 22-26; Applicants note that this document is cited and discussed in the present application, beginning at page 1, line 22;

(16) VANDERSCHUREN et al. "Alterations in Dopaminergic and Glutamatergic Transmission in the Induction and Expression of Behavioral Sensitization: A Critical Review of Preclinical Studies", Psychopharmacology, vol. 151, 2000, pp. 99-120; Applicants note that this document is cited and discussed in the present application, beginning at page 1, line 23;

(17) PIERCE et al. "A Circuitry Model of the Expression of Behavioral Sensitization to Amphetamine-like Psychostimulants", Brain Research Reviews, vol. 25, 1997, pp. 192-216; Applicants note that this document is cited and discussed in the present application, beginning at page 1, line 23;

(18) JAYANTHI et al. "The *Caenorhabditis elegans* Gene *T23G5.5* Encodes an Antidepressant- and Cocaine-Sensitive Dopamine Transporter", Molecular Pharmacology, vol. 54, 1998, pp. 601-609; Applicants note that this document is cited and discussed in the present application, beginning at page 2, line 31;

(19) NASS et al. "The *Caenorhabditis elegans* Dopaminergic System: Opportunities for Insights into Dopamine Transport and Neurodegeneration", Annu. Rev. Pharmacol. Toxicol, vol. 43, 2003, pp. 521-544; Applicants note that this document is cited and discussed in the present application, beginning at page 2, line 32;

(20) RANKIN et al. "*Caenorhabditis elegans*: A New Model System for the Study of Learning and memory", Behavioral Brain Research, vol. 37, 1990, pp. 89-92; Applicants note that this document is cited and discussed in the present application, beginning at page 3, line 5;

(21) HOBERT "Behavioral Plasticity in *C. elegans*: Paradigms, Circuits, Genes", Journal of Neurobiology, vol. 54, 2003, pp. 203-223; Applicants note that this document is cited and discussed in the present application, beginning at page 3, line 5;

(22) ROBINSON et al. "Alterations in the Morphology of Dendrites and Dendritic Spines in the Nucleus Accumbens and Prefrontal Cortex Following Repeated Treatment with Amphetamine or Cocaine", European Journal of Neuroscience, vol. 11, 1999, pp. 1598-1604; Applicants note that this document is cited and discussed in the present application, beginning at page 3, line 10.

Copies of the above-listed documents are enclosed together with a completed copy of the PTO-1449 Form listing these documents. Accordingly, the Examiner is requested to consider these documents and to indicate such consideration by returning a signed and initialed copy of the PTO-1449 Form with the next official communication.

Applicants note that an Office Action on the merits has not yet issued in the instant application, and thus, no fee is necessary to ensure consideration of this statement. However, if an Office Action has issued and is crossing in the mail with this statement, the Patent and Trademark Office is hereby authorized to charge Deposit Account No. 19-0089 any fee necessary to ensure consideration of the submitted materials.

If there should be any questions, the Examiner is invited to contact the undersigned at the telephone number listed below.

Respectfully submitted,
Ikue MORI et al



Bruce H. Bernstein
Reg. No. 29,027

February 5, 2008
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Stephen M. Roylance
Reg. No. 31,296